Doris Kim

Doris Kim has extensive experience in translational science, companion diagnostics, and oncology biomarker development. Doris began their career as a Research Associate at the University of California, San Francisco in 2004, focusing on pediatric research. In 2009, they transitioned to the Department of Medicine at the same institution as a Research Specialist, where they investigated the pathogenesis and therapeutic response of activated tyrosine kinases in adult and pediatric blood disorders.

In 2011, Doris joined Genentech, where they held multiple roles. As a Senior Scientific Researcher in Oncology Biomarker Development, they designed and executed molecular diagnostic assays and worked with bioinformatics and clinical teams to gain insights into large multi-parameter datasets in colorectal and bladder cancer. Doris then became the Principal Development Leader for Companion Diagnostics (CDx) and later the CDx Signaling Oncology Franchise Leader, guiding the strategy and implementation of multiple companion diagnostics in support of Roche/Genentech's therapeutic portfolios.

Currently, Doris is employed at Zentalis Pharmaceuticals as the Executive Director of Translational Science and Head of Companion Diagnostics. Doris plays a crucial role in developing strategies and overseeing the implementation of translational science and companion diagnostics.

Throughout their career, Doris has demonstrated their expertise in In Vitro Diagnostics (IVD) and Companion Diagnostic (CDx) development, as well as their knowledge of FDA/EMA regulations for diagnostic testing in registrational studies. Doris has also published academic papers and filed patents related to their work in biomarker development.

Doris Kim obtained their B.A. in Molecular & Cell Biology from the University of California, Berkeley from 2000 to 2004. Doris also pursued a Post-Baccalaureate degree in Physiology at San Francisco State University. No specific start and end years were provided for this program.